Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're paying for Wegovy out of your own pocket, you're in the majority. Most people accessing semaglutide for weight loss in the UK do so privately, because NHS eligibility is still limited to specific clinical criteria and services. Self-pay gives you faster access, no waiting list, and full control over the process — though it comes with a real cost that's worth understanding before you start. Wegovy is a prescription-only medicine, so every legitimate self-pay route still requires a clinical assessment and a prescription from a qualified prescriber. Wegovy's licensed use in the UK covers adults with a BMI of 30 or above, or 27 and above if you have a weight-related condition such as high blood pressure or type 2 diabetes.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The NHS does recommend semaglutide (Wegovy) for weight management under NICE Technology Appraisal 875, but the conditions attached are strict. NICE specifies that it should be offered within a specialist weight management service, with multidisciplinary support, for a maximum of two years, and generally for people with a BMI of 35 or above and at least one weight-related comorbidity. Waiting lists for those services are long in most areas. That gap (between the medicine existing and most people being able to access it) is where private self-pay sits.
If you don't meet the NHS thresholds, or you'd rather not wait, a private prescription is the legal route. Plenty of people who do technically qualify still choose to pay privately simply because the speed and convenience matter to them. That's a reasonable choice, and it's one our clinical team at nume sees made regularly.
Wegovy is prescribed as a once-weekly injection, starting at 0.25mg and increasing in stages up to the standard 2.4mg maintenance dose, with 7.2mg now also approved by the MHRA for eligible adults. Your monthly outlay depends on which dose you're on, and it changes as your prescription progresses.
Private prices across UK providers have risen meaningfully since 2024. Across the market, self-pay Wegovy is typically priced somewhere between £150 and £350 or more per month depending on dose and provider. Those figures are rough market context; they are not fixed, and they move. The more important question is what's included. Some providers charge separately for the consultation, the prescription, delivery, and any follow-up support. Others, like private Wegovy services that bundle everything, quote a single all-in price. A full breakdown of what drives Wegovy pricing is worth reading before you commit to any provider.
The honest acknowledgement here: if you've looked at the numbers and felt a quiet anxiety about sustaining the cost month after month, you're not alone. It's a real consideration. The right service should make it easy to pause, re-evaluate, and never charge you for something you haven't agreed to.
Wegovy is a prescription-only medicine. That means any seller offering it without a clinical assessment is operating outside the law, and the medicine you'd receive might not be genuine. The MHRA has seized large quantities of fake weight-loss pens sold via social media and unregistered websites, some of which were found to contain insulin rather than semaglutide. You can read the MHRA's own guidance on safe sourcing at the Yellow Card site, where you can also report suspicious sellers.
The simplest check: look up any online pharmacy on the GPhC register before handing over payment or personal information. A registered pharmacy will have a GPhC premises number you can verify directly. If a provider is reluctant to share that, walk away. Red flags include prices far below the market, no visible prescriber review, and promotions that feel more like a sale than a clinical service.
For a practical guide to choosing where to buy, this page on where to get Wegovy safely in the UK covers what to check before you order.
Not necessarily. Some services offer payment options that spread the cost of each order. Paying for Wegovy in instalments is possible through certain providers, which can make a higher dose more manageable in a given month. These are typically buy-now-pay-later arrangements tied to individual orders rather than subscriptions, so they apply to a single purchase, not an ongoing commitment.
Worth knowing: at nume, there are no subscriptions and no automatic renewals. Every repeat order goes through a fresh clinical review, and monthly payment options are available to help with flexibility. What self-pay should never mean is signing up to something you can't easily stop. The FAQs cover this in more detail if you have questions about how ordering works in practice.
If you're ready to find out whether Wegovy is clinically suitable for you, start your free consultation, a GPhC-registered prescriber reviews your answers the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.